Vaccinex, Inc.
EARLY DETECTION OF GLIAL CELL ACTIVATION IN NEURODEGENERATIVE OR NEUROINFLAMMATORY DISEASES

Abstract:

The disclosure provides a method for determining the efficacy of treatment with a SEMA4D antagonist, e.g., a SEMA4D antagonist antibody in the treatment of a neuroinflammatory or neurodegenerative disease, disorder, or injury, where the method provides differential measurement of glucose uptake in the brain, e.g., by FDG-PET imaging.